NCT02561481View on ClinicalTrials.gov

Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2020

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Sulforaphane

See under active arm description

DRUG

Placebo

See under placebo arm description

Trial Locations (1)

01655

University of Massachusetts Medical School, Worcester

All Listed Sponsors
collaborator

Congressionally Directed Medical Research Programs

FED

collaborator

Johns Hopkins University

OTHER

lead

University of Massachusetts, Worcester

OTHER

NCT02561481 - Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD) | Biotech Hunter | Biotech Hunter